Compare EOLS & EOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EOLS | EOD |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.3M | 271.7M |
| IPO Year | 2018 | N/A |
| Metric | EOLS | EOD |
|---|---|---|
| Price | $6.39 | $6.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $15.50 | N/A |
| AVG Volume (30 Days) | ★ 910.2K | 121.0K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.28% |
| EPS Growth | ★ 1.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $297,176,000.00 | N/A |
| Revenue This Year | $13.27 | N/A |
| Revenue Next Year | $17.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.61 | N/A |
| 52 Week Low | $3.86 | $5.14 |
| 52 Week High | $10.62 | $6.49 |
| Indicator | EOLS | EOD |
|---|---|---|
| Relative Strength Index (RSI) | 75.11 | 64.58 |
| Support Level | $5.88 | $5.56 |
| Resistance Level | $6.40 | N/A |
| Average True Range (ATR) | 0.36 | 0.12 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 80.54 | 95.71 |
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.